[DOI] [PubMed] [Google Scholar] 4.Zebovitz E
Semaglutide binding was determined using surface plasmon resonance biosensor technology (Biacore T100 Instrument, GE Healthcare Bio-Sciences AB, Ume, Sweden), in which semaglutide was immobilized at the surface and diluted plasma, collected prior to dosing, was passed over the sensor chip

The incidence varies considerably between different medications and doses: Semaglutide (Ozempic): Vomiting occurs in approximately 5-10% of patients at diabetes doses Semaglutide (Wegovy): At the higher weight management dose (2.4mg), vomiting affects up to 16% of patients Liraglutide (Victoza): Vomiting affects approximately 5% of patients Liraglutide (Saxenda): At weight management doses, vomiting occurs in about 7-10% of patients Dulaglutide (Trulicity): Vomiting affects approximately 7-9% of patients Tirzepatide (Mounjaro): Vomiting occurs in approximately 5-10% of patients, varying by dose These side effects are most pronounced during the initial treatment phase, particularly in the first 48 weeks, and often diminish as the body adapts to the medication
Hyperhidrosis causes excessive sweating, often in hands, feet, armpits, or faceeven at rest